Compare

Afya/$AFYA

1D1W1M3M6MYTD1Y5YMAX

About Afya

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Ticker
$AFYA
Sector
Consumer Discretionary
Primary listing
NASDAQ
Employees
9,395
Headquarters
Belo Horizonte, Brazil
Website
www.afya.com.br

Afya Metrics

BasicAdvanced
$925M
6.57
$1.59
0.38
$0.66
6.28%

What the Analysts think about Afya

Analyst ratings (Buy, Hold, Sell) for Afya stock.
Analyst projections of the future price of Afya stock.

Bulls say / Bears say

First-half revenue rose 7% (6.6% excluding acquisitions), helped by a 3.9% increase in medical-school fees and 18% growth in health-sciences enrolment. Afya reaffirmed its 2026 revenue and EBITDA guidance. (SEC)
Afya generated strong cash and returned R$447.9 million through dividends and buybacks in the first half, while net debt excluding IFRS 16 was broadly stable. Repurchases covered about 3% of shares outstanding under the programme, supporting per-share returns. (SEC)
If completed, the agreed Yduqs combination would create a much larger education platform, with about 1.6 million students and 38,000 medical students. Its scale and broader reach could support future growth, though the deal remains subject to approvals. (Yduqs, SEC)
Profitability is growing more slowly than sales: first-half adjusted EBITDA rose 2.8% against 7% revenue growth, while the EBITDA margin fell 190 basis points to 46.2%. The second-quarter margin also contracted, reflecting higher investment and marketing costs. (SEC)
Afya faces medical-course quality and regulatory risk: 11 of its courses received an unsatisfactory first Enamed score. Brazilian authorities have restored enforcement measures that can restrict admissions, funded places and seat numbers at underperforming courses. (Melhores Escolas Médicas, Agência Brasil)
The Yduqs merger is not assured: it needs antitrust and shareholder approvals, and its scale could bring competition and governance scrutiny. Any expected benefits depend on securing approval and integrating the businesses successfully. (Valor International, Yduqs)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.

Afya Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Afya Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Afya News

AllArticlesVideos

Afya Maps Yduqs Merger, BRL 2.2B Synergies and Digital Health Growth at Investor Day

MarketBeat1 week ago

Afya Limited and YDUQS Participações S.A. Controlling Shareholders Enter Into Voting Commitment Agreement

Business Wire1 month ago

Merger Agreement and Other Covenants Entered Into by and Between AFYA LIMITED and YDUQS PARTICIPAÇÕES S.A.

Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.